AltMountain

Lynx1 Capital Management LP

Dorado, PR · CRD 310301
Hedge fund manager

Lynx1 Capital Management LP is an SEC-registered investment adviser based in Dorado, PR that reports managing 1 hedge fund on Form ADV. It reports $626.7 million in regulatory assets under management. Its private funds, of all types, hold $576.8 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +51.0% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +73.6% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$626.7 millionForm ADV Item 5.F
Gross assets of private funds
$576.8 millionAll private fund types, Form ADV
Hedge funds managed
12 private funds in total
Employees
5Form ADV Item 5.A
Registration
SEC-registered adviserCRD 310301
Latest Form ADV
10/07/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+51.0%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+73.6%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$865.5 million27 positions, 2026-06-30
$59$116$174Q3 2024Q1 2025Q3 2025Q1 202613F est. $174S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+33.9%+14.8%
Q1 2026+12.8%-4.6%
Q4 2025+11.0%+2.4%
Q3 2025+49.4%+7.8%
Q2 2025+17.0%+10.4%
Q1 2025-18.2%-4.5%
Q4 2024-17.5%+2.1%
Q3 2024-12.3%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 31 share positions ($646,092,908) reported by Lynx1 Capital Management LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • GH Research PLC48.20%
  • Cullinan Therapeutics Inc21.30%
  • Stoke Therapeutics Inc15.68%
  • C4 Therapeutics Inc3.88%
  • Precision Biosciences Inc2.67%
  • Agios Pharmaceuticals Inc2.43%
  • Korro Bio Inc2.37%
  • Neuphoria Therapeutics Inc0.48%
  • Passage Bio Inc0.47%
  • Proqr Thrapeutics N V0.40%
StockValue% of 13F portfolioSharesShares vs prior quarter
GH Research PLC$311,422,00248.20%13,263,288Unchanged
Cullinan Therapeutics Inc$137,589,72521.30%8,963,500Unchanged
Stoke Therapeutics Inc$101,300,39415.68%3,896,169-3.52%
C4 Therapeutics Inc$25,077,9473.88%7,530,915+2.79%
Precision Biosciences Inc$17,266,4262.67%2,758,215+190.20%
Agios Pharmaceuticals Inc$15,714,1502.43%472,606-86.14%
Korro Bio Inc$15,310,7522.37%1,544,980+0.43%
Neuphoria Therapeutics Inc$3,116,1680.48%875,328Unchanged
Passage Bio Inc$3,031,9140.47%673,759Unchanged
Proqr Thrapeutics N V$2,593,0740.40%1,562,093+199.59%
Tscan Therapeutics Inc$2,522,0220.39%8,019,148Unchanged
Kazia Therapeutics LTD$2,166,5510.34%225,800New
Pliant Therapeutics Inc$1,941,9160.30%1,798,070Unchanged
Entrada Therapeutics Inc$1,769,1480.27%278,606+55.99%
Surrozen Inc$643,6000.10%20,000New
Immatics N.V$625,6890.10%71,263+206.69%
Werewolf Therapeutics Inc$606,6760.09%657,786Unchanged
Yarrow Bioscience Inc$495,4400.08%22,000New
Xencor Inc$453,9400.07%18,194Unchanged
Immunocore Hldgs PLC$433,1470.07%14,300New
Dyne Therapeutics Inc$402,7500.06%25,000New
Traws Pharma Inc$332,2130.05%559,470Unchanged
Denali Therapeutics Inc$240,9710.04%11,658Unchanged
Absci Corporation$228,8090.04%21,245Unchanged
Foghorn Therapeutics Inc$219,8690.03%61,588Unchanged
Avalo Therapeutics Inc$154,8330.02%10,100Unchanged
Prime Medicine Inc$137,4750.02%45,000New
Bolt Biotherapeutics Inc$113,3440.02%30,800Unchanged
Eupraxia Pharmaceuticals Inc$91,0000.01%10,000Unchanged
Nuvation Bio Inc$89,7620.01%16,029Unchanged
Inhibikase Therapeutics Inc$1,2010.00%20,000Unchanged

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 6 new positions, 2 sold out, 6 increased, 2 reduced and 17 unchanged.

Number of positions (a count, not dollars)

  • New positions6
  • Increased6
  • Unchanged17
  • Reduced2
  • Sold out2

New positions

StockValueShares
Kazia Therapeutics LTD$2,166,551225,800
Surrozen Inc$643,60020,000
Yarrow Bioscience Inc$495,44022,000
Immunocore Hldgs PLC$433,14714,300
Dyne Therapeutics Inc$402,75025,000
Prime Medicine Inc$137,47545,000

Sold out

StockValue at Jun 30, 2026Shares held then
CG Oncology Inc$2,230,33131,391
Vyne Therapeutics Inc$1,059,7951,628,700

Largest increases

StockChange in sharesChangeValue nowShares now
Precision Biosciences Inc+1,807,749+190.20%$17,266,4262,758,215
Proqr Thrapeutics N V+1,040,680+199.59%$2,593,0741,562,093
C4 Therapeutics Inc+204,224+2.79%$25,077,9477,530,915
Entrada Therapeutics Inc+100,000+55.99%$1,769,148278,606
Immatics N.V+48,027+206.69%$625,68971,263
Korro Bio Inc+6,684+0.43%$15,310,7521,544,980

Largest reductions

StockChange in sharesChangeValue nowShares now
Agios Pharmaceuticals Inc-2,936,331-86.14%$15,714,150472,606
Stoke Therapeutics Inc-142,235-3.52%$101,300,3943,896,169

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Precision Biosciences Inc13G amendment9.9%2,758,215Nov 16, 2026SEC.gov ↗
Agios Pharmaceuticals, Inc.13G amendment0.8%472,606Nov 16, 2026SEC.gov ↗
TScan Therapeutics, Inc.13G amendment13.1%20,519,148Aug 14, 2026SEC.gov ↗
Stoke Therapeutics, Inc.13G amendment6.5%4,038,404Aug 14, 2026SEC.gov ↗
C4 Therapeutics, Inc.13G amendment9.99%15,423,691Aug 14, 2026SEC.gov ↗
iBio, Inc.13G5.4%2,807,016Aug 14, 2026SEC.gov ↗
GH Research PLC13G amendment19.3%13,263,288Aug 14, 2026SEC.gov ↗
Passage BIO, Inc.13D21%673,759Jul 2, 2026SEC.gov ↗
Allogene Therapeutics, Inc.13G amendment0%0May 15, 2026SEC.gov ↗
Korro Bio, Inc.13G amendment10.7%1,538,296Apr 2, 2026SEC.gov ↗
Neuphoria Therapeutics Inc.13D amendment16.3%875,328Dec 29, 2025SEC.gov ↗
Cullinan Therapeutics, Inc.13G amendment9.8%5,766,090Nov 14, 2025SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Nov 14, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (2)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (2)

As reported in the adviser's Form ADV filed Aug 7, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌​‌‌‌‌‌‌‌‌‌‌⁠